AI
RYTM icon

Axiom Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Axiom Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.98M Buy
91,749
+8,195
+10% +$797K 0.09% 88
2025
Q4 		$8.94M Buy
83,554
+523
+0.6% +$55.5K 0.08% 87
2025
Q3 		$8.39M Buy
83,031
+30,571
+58% +$2.84M 0.06% 87
2025
Q2 		$3.31M Buy
+52,460
New +$3.21M 0.03% 107

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Axiom Investors's RYTM Position: Q1 2026 in Review

Axiom Investors increased its Rhythm Pharmaceuticals (RYTM) stake by 9.8% in Q1 2026, buying an estimated $797K and bringing the position to 91,749 shares worth $7.98M. The position accounts for 0.09% of the portfolio, ranked #88.

Axiom Investors first reported a position in RYTM in Q2 2025 and has held it in 4 quarters since. The position peaked at $8.94M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Axiom Investors held 91,749 shares of Rhythm Pharmaceuticals worth $7.98M as of Q1 2026.
  • Axiom Investors bought 8,195 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $797K.
  • Rhythm Pharmaceuticals made up 0.09% of Axiom Investors's portfolio in Q1 2026, its #88 holding.
  • Axiom Investors first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Axiom Investors's Rhythm Pharmaceuticals position peaked at $8.94M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Axiom Investors's 13F filing for Q1 2026, filed 14 May 2026.